Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CSF3R T618I CSF3R Q749* |
Therapy | Ruxolitinib |
Indication/Tumor Type | chronic neutrophilic leukemia |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CSF3R T618I CSF3R Q749* | chronic neutrophilic leukemia | predicted - sensitive | Ruxolitinib | Case Reports/Case Series | Actionable | In a clinical case study, Jakafi (ruxolitinib) treatment resulted in hematologic remission for at least 3 years in a patient with chronic neutrophilic leukemia harboring CSF3R T618I and Q749* along with DNMT3A R882C (PMID: 32577845). | 32577845 |
PubMed Id | Reference Title | Details |
---|---|---|
(32577845) | Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation. | Full reference... |